| 1.57 -0.09 (-5.42%) | 04-20 11:22 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.04 | 1-year : | 2.38 |
| Resists | First : | 1.75 | Second : | 2.04 |
| Pivot price | 1.46  |
|||
| Supports | First : | 1.39 | Second : | 1.16 |
| MAs | MA(5) : | 1.63 |
MA(20) : | 1.41 |
| MA(100) : | 1.66 |
MA(250) : | 1.88 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 74.6 |
D(3) : | 79.9 |
| RSI | RSI(14): 56 |
|||
| 52-week | High : | 2.63 | Low : | 1.16 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IPHA ] has closed below upper band by 28.2%. Bollinger Bands are 106.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.71 - 1.72 | 1.72 - 1.72 |
| Low: | 1.58 - 1.59 | 1.59 - 1.6 |
| Close: | 1.65 - 1.66 | 1.66 - 1.67 |
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Fri, 17 Apr 2026
Innate Pharma (Nasdaq: IPHA) highlights MATISSE IPH5201 lung cancer data at AACR - Stock Titan
Mon, 13 Apr 2026
Innate Pharma (Nasdaq: IPHA) reports 93.9M shares and voting rights update - Stock Titan
Mon, 13 Apr 2026
Innate Pharma (Nasdaq: IPHA) schedules 2026 AGM and lab tour - Stock Titan
Mon, 13 Apr 2026
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026 - WFXG
Mon, 13 Apr 2026
Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026 - Business Wire
Fri, 10 Apr 2026
[SCHEDULE 13G/A] Innate Pharma SA Amended Passive Investment Disclosure - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 94 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 71 (K) |
| Shares Short P.Month | 99 (K) |
| EPS | -0.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.28 |
| Profit Margin | 0 % |
| Operating Margin | -689.6 % |
| Return on Assets (ttm) | -38.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -46.8 % |
| Gross Profit (p.s.) | -0.37 |
| Sales Per Share | 0.09 |
| EBITDA (p.s.) | -0.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -2.44 |
| PEG Ratio | 0 |
| Price to Book value | -5.86 |
| Price to Sales | 16.45 |
| Price to Cash Flow | -2.81 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|